ArticleEXCLI journal2021

Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis.

Jun Guan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.